FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Sunday

 

Merck KGaA to try again to get approval for MS pill cladribine




























Image Source:  CLADRIBINE

Germany's Merck KGaA is to seek approval from Europe's regulators for the use of its cladribine tablet to treat multiple sclerosis, in a fresh attempt to enter a multi-billion dollar market for a drug it had given up on four years ago.

In 2011 U.S. drug regulators' concerns about whether cladribine could cause cancer put an end to Merck's development and marketing plans for the drug.

At the time, it was conducting Phase III trials, which the company says have since yielded new insights.

"The decision follows the company's evaluation of new data and additional analyses of the compound's benefit-risk profile," the company said in a statement.

A spokeswoman declined to comment further on the findings or where the new data came from. Fresh trials were not carried out.

But the move signals confidence that cladribine could hold its own in an oral MS drugs market that has become increasingly crowded since Merck pulled the plug on its project in 2011.

Biogen's Tecfidera, with $2.9 billion in sales last year, looks the strongest contender in the class after it became the third oral MS drug to get to market after Gilenya from Novartis, with $2.5 billion in sales, and Sanofi's Aubagio, with 433 million euros ($489 million) in sales.

All three are taking market share from established injectable MS drugs such as Merck KGaA's Rebif, Teva's Copaxone and Bayer's Betaferon/Betaseron.

Merck said it sent a letter of intent to European healthcare regulators to meet certain requirements before it can submit the official request for approval.

The company is also looking to seek approvals in other markets.

The additional costs of getting approval are limited because Merck has already finished the third and last stage of testing on humans that is required for approval, and which is by far the most expensive phase during the development cycle.

Story Source: The above story is based on materials provided by YAHOONEWS
Note: Materials may be edited for content and length


Go to Newer News Go to Older News